Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up
Lerner, A.Martin.; Beqaj, S.H.; Deeter, R.G.; Fitzgerald, J.T.
In Vivo 21(5): 707-713
2007
ISSN/ISBN: 0258-851X PMID: 18019402 Document Number: 613883
Background: We hypothesized that subset classification of Epstein-Barr virus (EBV) in chronic fatigue syndrome (CFS) is required. At first, a blinded-random placebo-controlled trial of valacyclovir in EB V CFS subset was performed (Group 1), and this EBV subset was followed for thirty-six months (Group 2). Patients were given valacyclovir at 14.3 mg/kg every 6 hours. The validated Energy Index (EI) point score assessing physical functional capacity, Holter monitor, multigated (radionuclide) MUGA rest/stress ventriculographic examination, EBV serum IgM viral capsid antibodies (VCA), and EBV early antigen diffuse (EA) were followed. After six-months, Group 1 CFS patients receiving valacyclovir experienced an increased mean least square EI point score +1.12 units (122 kcal/day), while the placebo cohort increased + 0. 42 EI units (65 kcal/day). EI point scores at Group 2 increased progressively. Sinus tachycardia's decreased and abnormal cardiac wall motion improved Serum antibody titers to EBV VCA IgM decreased. Patients resumed normal activities.